Market Closed -
Other stock markets
|
After market 12:54:34 pm | |||
0.41 EUR | -2.84% | 0.41 | 0.00% |
Apr. 05 | GenSight: financial visibility assured until the end of April | CF |
Mar. 25 | GenSight: share price falls, limited financial visibility | CF |
Sales 2023 | 3M 3.2M | Sales 2024 * | 4.4M 4.69M | Capitalization | 32.96M 35.13M |
---|---|---|---|---|---|
Net income 2023 | -26M -27.71M | Net income 2024 * | -26M -27.71M | EV / Sales 2023 | 8.55 x |
Net Debt 2023 * | 29.4M 31.33M | Net Debt 2024 * | 57.8M 61.6M | EV / Sales 2024 * | 20.6 x |
P/E ratio 2023 |
-0.85
x | P/E ratio 2024 * |
-0.74
x | Employees | 23 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 90.77% |
Latest transcript on GenSight Biologics S.A.
1 day | -2.84% | ||
1 week | +2.50% | ||
Current month | +1.99% | ||
1 month | -12.58% | ||
3 months | +1.74% | ||
6 months | -41.09% | ||
Current year | -10.87% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 21-05-18 | |
Thomas Gidoin
DFI | Director of Finance/CFO | 41 | 15-05-31 |
Scott Jeffers
CTO | Chief Tech/Sci/R&D Officer | - | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 13-09-30 |
Peter Goodfellow
BRD | Director/Board Member | 72 | 14-05-31 |
José-Alain Sahel
FOU | Founder | 68 | 11-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 0.41 | -2.84% | 55 094 |
24-04-17 | 0.422 | +6.03% | 89,644 |
24-04-16 | 0.398 | -1.00% | 42,290 |
24-04-15 | 0.402 | +0.63% | 19,740 |
24-04-12 | 0.3995 | -0.13% | 25,442 |
Real-time Euronext Paris, April 18, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.87% | 35.07M | |
-3.23% | 102B | |
+2.61% | 96.84B | |
-0.44% | 21.48B | |
-18.50% | 20.82B | |
-7.45% | 18.6B | |
-40.70% | 16.81B | |
-25.71% | 13.78B | |
+0.95% | 13.4B | |
+22.65% | 11.06B |
- Stock Market
- Equities
- SIGHT Stock